Overview
The Anticonvulsant Drug Development (ADD) Program is an established laboratory experienced in the preclinical identification and evaluation of investigational compounds for the treatment of epilepsy. Current investigators at the program have held multiple contracts with biopharmaceutical and government partners for testing of novel compounds in seizure models. The program has considerable experience in performing efficacy and tolerability assessments of novel and established antiseizure drugs (ASDs) using multiple routes of administration [intraperitoneal (i.p.), intravenous (i.v.), oral (per os, p.o.), subcutaneous (s.c.), intramuscular (i.m.), and intracerebroventricular (i.c.v.)] in models for epilepsy.
To learn more about the ADD program visit https://pharmacy.utah.edu/add/
\
